Customized API development and manufacturing services

We are an industry-leading integrated development and manufacturing service provider for small molecule drug substances and their intermediates.

Chemistry is core to us. Our track record in producing API and intermediates extends back to the genesis of contract development and manufacturing. Thousands of compounds have been successfully developed and progressed by our R&D, process development and manufacturing teams. Many of these molecules have been scaled under accelerated timelines to meet program objectives. 

We recognize that chemical synthesis accounts for the majority of the drugs on the market today, as well as in the drug development pipeline. And we recognize that today’s drug compound candidates are increasingly complex and can require specialized handling and protocols. That’s why we offer flexible development and manufacturing services across a wide range of chemical synthesis.

We also appreciate that every drug program is different and our customers require more agility and adaptiveness than ever before. We continue to meet this challenge through our investments in world-class infrastructure, technologies and teams to support your small molecule needs from proof of concept through commercialization.

LPB-A.06_SmallMoleculeTimeline (1)
Lonza Small Molecule Capabilities: Drug Substance to Drug Product, Parenteral to Oral

Introduction to Small Molecules

On-demand webinar

Extensive and flexible manufacturing services

We have an established history and ongoing service programs with the full range of customers from virtual companies to big pharma. Our development and manufacturing services routinely support:

  • drug substances requiring advanced synthesis expertise and process development
  • late phase clinical programs requiring the scale and expertise provided by Lonza for rapid commercialization
  • highly potent compounds requiring our specialized infrastructure and handling capabilities
  • ADC payloads with the option of integrated services inclusive of monoclonal antibodies, inkers and conjugation services.  

Phase-appropriate assets support all phases of drug substance development and supply.

Fully integrated services are in place to meet all of the development and manufacturing needs for drug substances and intermediates:

Technologies and products

We have supported more than 30% of recent small molecule launches with breakthrough designations.

small molecules and intermediates

World class, extensive infrastructure is also in place at our Visp, Switzerland and Nansha, China facilities to ensure fit-for-purpose supply to a global customer base. Phase-appropriate assets support all phases of drug substance development, and a focus on manufacturability ensures that our processes are rapidly scalable.

Visp, Switzerland

Production, Research & Development, Sales & Support

Visp 3930

Nansha, China

Production, Research & Development

Huangge N Ave
Guangzhou, Nansha 511455